Akari Therapeutics annual return on equity
2006
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Akari Therapeutics Return on Equity (ROE) Growth & History (AKTX)
Akari Therapeutics's return on equity was −68.43% for fiscal 2025.
View full Akari Therapeutics company overviewAkari Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −68.43% | +111.49 pp |
| 2024 | 2024-12-31 | −179.92% | +1101.52 pp |
| 2023 | 2023-12-31 | −1,281.43% | −798.23 pp |
| 2022 | 2022-12-31 | −483.20% | −249.93 pp |
| 2021 | 2021-12-31 | −233.27% | +215.55 pp |
| 2020 | 2020-12-31 | −448.82% | +848.92 pp |
| 2019 | 2019-12-31 | −1,297.73% | −1143.62 pp |
| 2018 | 2018-12-31 | −154.11% | −28.44 pp |
| 2017 | 2017-12-31 | −125.67% | −81.86 pp |
| 2016 | 2016-12-31 | −43.81% | +134.11 pp |
| 2015 | 2015-12-31 | −177.92% | −29.47 pp |
| 2014 | 2014-12-31 | −148.44% | — |
| 2006 | 2006-12-31 | −461.88% | — |
Akari Therapeutics quarterly return on equity
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q2.17
Q2.18
Q2.19
Q2.20
Q3.20
Q4.20
Q2.21
Q2.22
Q2.23
Q4.23
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −29.16% | −21.15 pp |
| Q1 2026 | 2026-03-31 | −67.69% | −50.84 pp |
| Q4 2025 | 2025-12-31 | −20.77% | +27.79 pp |
| Q3 2025 | 2025-09-30 | −26.51% | — |
| Q2 2025 | 2025-06-30 | −8.00% | — |
| Q1 2025 | 2025-03-31 | −16.85% | — |
| Q4 2024 | 2024-12-31 | −48.56% | +275.73 pp |
| Q4 2023 | 2023-12-31 | −324.29% | — |
| Q2 2023 | 2023-06-30 | −174.98% | −93.14 pp |
| Q2 2022 | 2022-06-30 | −81.84% | −2.62 pp |
| Q2 2021 | 2021-06-30 | −79.22% | +276.33 pp |
| Q4 2020 | 2020-12-31 | −83.39% | — |
| Q3 2020 | 2020-09-30 | 14.16% | — |
| Q2 2020 | 2020-06-30 | −355.55% | +41.46 pp |
| Q2 2019 | 2019-06-30 | −397.01% | −345.02 pp |
| Q2 2018 | 2018-06-30 | −51.99% | −50.86 pp |
| Q2 2017 | 2017-06-30 | −1.12% | +13.72 pp |
| Q2 2016 | 2016-06-30 | −14.84% | +60.31 pp |
| Q1 2016 | 2016-03-31 | −6.28% | +64.15 pp |
| Q4 2015 | 2015-12-31 | 14.34% | −156.74 pp |
| Q3 2015 | 2015-09-30 | −230.40% | — |
| Q2 2015 | 2015-06-30 | −75.16% | — |
| Q1 2015 | 2015-03-31 | −70.43% | — |
| Q4 2014 | 2014-12-31 | 171.08% | — |
Akari Therapeutics return on equity trends
Over the last five fiscal years, Akari Therapeutics's return on equity increased from −448.82% to −68.43%, a change of +380.39 percentage points. The latest reported quarter, Q2 2026, shows −29.16%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Akari Therapeutics source filings ↗